The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

British Journal of Haematology

Volumn 169, Issue 3, 2015, Pages 455-458

  Daneshmanesh, Amir Hossein ^a   Hojjat Farsangi, Mohammad ^a   Moshfegh, Ali ^a   Khan, Abdul Salam ^a   Mikaelsson, Eva ^a   Österborg, Anders ^a   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Chronic lymphocytic leukaemia; Monoclonal antibodies; PI3K AKT mTOR pathway; ROR1

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; PROTEIN TYROSINE KINASE; RTK LIKE ORPHAN RECEPTOR 1; UNCLASSIFIED DRUG; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTIGEN EXPRESSION; APOPTOSIS; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INTERACTION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; GENE SILENCING; HUMAN; LETTER; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM;

ANTIBODIES, MONOCLONAL; APOPTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84927608950     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13228     Document Type: Letter

References (10)

1. Arcaro, A. & Guerreiro, A.S. (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Current Genomics, 8, 271-306.
2. Choudhury, A., Derkow, K., Daneshmanesh, A.H., Mikaelsson, E., Kiaii, S., Kokhaei, P., Osterborg, A. & Mellstedt, H. (2010) Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. British Journal of Haematology, 151, 327-335.
3. Daneshmanesh, A.H., Mikaelsson, E., Jeddi-Tehrani, M., Bayat, A.A., Ghods, R., Ostadkarampour, M., Akhondi, M., Lagercrantz, S., Larsson, C., Osterborg, A., Shokri, F., Mellstedt, H. & Rabbani, H. (2008) Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. International Journal of Cancer, 123, 1190-1195.
4. Daneshmanesh, A.H., Hojjat-Farsangi, M., Khan, A.S., Jeddi-Tehrani, M., Akhondi, M.M., Bayat, A.A., Ghods, R., Mahmoudi, A.R., Hadavi, R., Osterborg, A., Shokri, F., Rabbani, H. & Mellstedt, H. (2012) Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia, 26, 1348-1355.
5. Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J.E., Widhopf, G.F. 2nd, Rassenti, L.Z., Cantwell, M.J., Prussak, C.E., Carson, D.A. & Kipps, T.J. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proceedings of the National Academy of Sciences of the United States of America, 105, 3047-3052.
6. Hojjat-Farsangi, M., Khan, A.S., Daneshmanesh, A.H., Moshfegh, A., Sandin, A., Mansouri, L., Palma, M., Lundin, J., Osterborg, A. & Mellstedt, H. (2013) The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS ONE, 8, e78339.
7. Widhopf, G.F. 2nd, Cui, B., Ghia, E.M., Chen, L., Messer, K., Shen, Z., Briggs, S.P., Croce, C.M. & Kipps, T.J. (2014) ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 111, 793-798.
8. Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H. & Takahashi, T. (2012) NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell, 21, 348-361.
9. Yang, J., Baskar, S., Kwong, K.Y., Kennedy, M.G., Wiestner, A. & Rader, C. (2011) Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE, 6, e21018.
10. Zhang, S., Chen, L., Wang-Rodriguez, J., Zhang, L., Cui, B., Frankel, W., Wu, R. & Kipps, T.J. (2012) The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. American Journal of Pathology, 181, 1903-1910.